High affinity peptide- containing nanoparticles

• US 20040126900A1
• Filed: 05/05/2003
• Published: 07/01/2004
• Est. Priority Date: 04/13/2001
• Status: Abandoned Application

• Current Assignee: Alnis Biosciences, Inc.
• Original Assignee: Alnis Biosciences, Inc.
• Inventors: Barry, Stephen E, Lindquist, Kevin, Casenas, Dominic, Goodwin, Andrew A, Decor, Rachel
• Application Number:
  US10/257,455
• Publication Number:
  US 20040126900A1
• Time in Patent Office: Days
• US Class Current: 436/523
• CPC Class Codes: A61K 47/62 the modifying agent being a protein, peptide or polyamino acid
• CPC Class Codes: A61K 47/6907 the form being a microemulsion, nanoemulsion or micelle
• CPC Class Codes: A61K 47/6935 the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: C07K 17/08 the carrier being a synthetic polymer
• CPC Class Codes: C07K 7/06 having 5 to 11 amino acids

Abstract

The present invention is directed to polymeric nanoparticles functionalized with two or more peptide moieties that possess high affinity to biomolecular targets, the peptide moieties being covalently linked to the nanoparticle polymeric core structure, either directly or via a linker molecule. The invention is further directed to methods of synthesizing these polymeric nanoparticles and to the various applications for which they may be used.

Claims

1. A water-soluble polymeric nanoparticle functionalized by at least two peptide moieties covalently linked to the nanoparticle polymeric core structure, the peptide moieties possessing high affinity to biomolecules.

2. A polymeric nanoparticle according to claim 1 wherein the peptide moieties possess high affinity to therapeutic proteins.

3. A polymeric nanoparticle according to claim 1 wherein the peptide moieties possess high affinity to proteins expressed on a cell or a tissue.

4. A polymeric nanoparticle according to claim 1 comprising at least two peptide moiety possessing high affinity to therapeutic proteins and at least two peptide moiety possessing high affinity to proteins expressed on a cell or a tissue.

7. A polymeric nanoparticle according to claim 1 wherein at least one of the peptide moieties comprises a peptide sequence selected from the group consisting of Arg-Gly-Asp-D Phe-Lys and Arg-Gly-Asp-D Phe-Lys-Cys.

8. A polymeric nanoparticle according to any of claims 1 to 7 wherein the polymeric core comprises a hydrophobic/hydrophilic block copolymer.

9. A polymeric nanoparticle according to claim 8 wherein the block copolymer comprises poly(amino acid).

10. A polymeric nanoparticle according to claim 9 wherein the poly(amino acid) comprises a hydrophobic block composed of hydrophobic or neutral amino acids, and random copolymers of any two of these;

and a hydrophilic block composed of hydrophilic amino acids.

11. A polymeric nanoparticle according to claim 8 wherein the block copolymer comprises a poly(amino acid) hydrophobic block and a polyethylene glycol hydrophilic block.

12. A polymeric nanoparticle according to claim 8 wherein the block copolymer comprises a polycaprolactone hydrophobic block and a polyethylene glycol hydrophilic block.

13. A polymeric nanoparticle according to any of claims 1 to 7 wherein the polymeric core comprises a crosslinked hydrophilic polymer.

14. A polymeric nanoparticle according to claim 13 wherein the hydrophilic polymer comprises crosslinked hydrophilic building blocks, at least some of the building blocks being carbohydrates.

15. A polymeric nanoparticle according to any of claims 1 to 14 characterized by having a high water content.

16. A polymeric nanoparticle according to any of claims 1 to 15 which further comprises at least one enhancer molecule covalently attached to the nanoparticle polymeric core structure.

17. A polymeric nanoparticle according to any of claim 1-16 which further comprises at least one polyethylene glycol molecule covalently attached to the nanoparticle polymeric core structure.

18. A polymeric nanoparticle according to any of claims 1 to 17 wherein the peptide moiety is covalently linked directly to a polymer molecule.

19. A polymeric nanoparticle according to any of claims 1 to 17 wherein the peptide moiety is covalently linked to a polymer molecule by a linker molecule.

20. A polymeric nanoparticle according to claim 19 wherein the linker molecule is a polyethylene glycol chain.

5. A water-soluble polymeric nanoparticle comprising i) at least two peptide moieties covalently linked to the nanoparticle polymeric core structure, each of the peptide moieties possessing high affinity to a therapeutic protein;

and ii) a therapeutic protein noncovalently linked to the peptide moiety and being at least partially enclosed within the nanoparticle.

6. A water-soluble polymeric nanoparticle according to claim 5 which is further functionalized with at least two additional peptide moieties covalently linked to the nanoparticle polymeric core structure, the additional peptide moieties possessing high affinity to proteins expressed on a cell or a tissue.

21. A method for the molecular recognition of a biomolecular target, the method comprising exposing the biomolecular target to a water-soluble polymeric nanoparticle functionalized by at least two peptide moieties covalently linked to the nanoparticle polymeric core structure, at least one of the peptide moieties possessing high affinity to proteins expressed on the biomolecular target.

22. A method for controllably releasing a therapeutic protein to an environment in a mammalian body, the method comprising administering to the environment a water-soluble polymeric nanoparticle comprising i) at least two peptide moieties covalently linked to the nanoparticle polymeric core structure, each of the peptide moieties possessing high affinity to the therapeutic protein;

and ii) the therapeutic protein noncovalently linked to the peptide moiety and being at least partially enclosed within the nanoparticle.

23. A method for the controlled delivery of a therapeutic protein to the vicinity of a targeted cell or tissue type, the method comprising administering to an environment containing the targeted cell or tissue type, a water-soluble polymeric nanoparticle comprising i) at least two first peptide moieties covalently linked to the nanoparticle polymeric core structure, each of the first peptide moieties possessing high affinity to the targeted cell or tissue type;

ii) at least two second peptide moieties covalently linked to the nanoparticle polymeric core structure, each of the second peptide moieties possessing high affinity to the therapeutic protein; and

iii) the therapeutic protein noncovalently linked to the second peptide moiety and being at least partially enclosed within the nanoparticle.

24. A method for synthesizing a water-soluble peptide-functionalized polymeric nanoparticle, the method comprising adding an aqueous phase containing hydrophilic building blocks, the building blocks comprising hydrophilic monomers with crosslinkable groups, to an organic solvent comprising at least one surfactant;

reacting the crosslinkable groups of the building blocks to covalently crosslink the building blocks to give a hydrophilic polymeric nanoparticle;

removing surfactant and the organic solvent;

adding peptide moieties to a solution containing the nanoparticle, the peptide moieties comprising a functionality for attachment to the nanoparticle and the peptide moieties possessing high affinity to proteins expressed on a cell or a tissue; and

reacting the peptide moieties and the nanoparticle to covalently bond the peptide and nanoparticle.

25. A method according to claim 24 wherein the aqueous phase further comprises therapeutic proteins and peptide moieties possessing high affinity to the therapeutic proteins.

26. A method according to claim 24 or 25 wherein at least some of the hydrophilic building blocks comprise carbohydrates.